ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2020 Annual Meeting of Stockholders held by ADMA Biologics, Inc. on June 18, 2020. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Market under the symbol "ADMA".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Two proposals were submitted to stockholders. As of the record date (April 24, 2020), 86,354,313 shares were outstanding, with 71,862,242 shares represented at the meeting, constituting a quorum.
- Proposal 1: Election of Class I Directors
- Bryant E. Fong: Elected with 35,678,649 votes "For", 1,170,307 "Withheld", and 35,013,286 Broker Non-Votes.
- Martha J. Demski: Elected with 35,280,778 votes "For", 1,568,178 "Withheld", and 35,013,286 Broker Non-Votes.
- Proposal 2: Ratification of Independent Auditor
- CohnReznick LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- Votes: 69,362,882 "For", 1,460,272 "Against", and 1,039,088 "Abstain".
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that Bryant E. Fong and Martha J. Demski were successfully elected to the Board of Directors.
- Verification that CohnReznick LLP is the appointed auditor for the fiscal year ending December 31, 2020.
- Review of the high number of Broker Non-Votes (35,013,286) relative to the "For" votes in the director election.